| Literature DB >> 32411201 |
Abstract
Endoscopic submucosal dissection (ESD) was also considered a "high risk" at the starting point with skillful endoscopic techniques and terrible complications. Still, it remains challenging yet has become widespread among institutes in many parts of the world. This study is aimed at further investigating the feasibility, efficacy, and safety of ESD of gastric lesions and at evaluating clinical outcomes in early experience. The patient characteristics, postoperative outcomes, and results of histopathological examinations were reviewed retrospectively between January 2017 and May 2019. Thirteen patients' gastric ESD were included with all of en bloc resections without recurrence. The long duration was related to the large lesion, the upper part of the stomach, and previous treatment. In this study, the ESD procedure of the stomach is a feasible and safe minimally invasive treatment option with organ preservation. It requires training and experience with a learning approach where skill may be improved to prevent unwanted complications.Entities:
Year: 2020 PMID: 32411201 PMCID: PMC7204261 DOI: 10.1155/2020/6873071
Source DB: PubMed Journal: Gastroenterol Res Pract ISSN: 1687-6121 Impact factor: 2.260
Figure 1Endoscopic submucosal dissection (ESD) procedure. (a) Endoscopic view of 28 mm 0-IIa lesion at lesser curvature, lower part of the stomach. (b) Narrow band imaging. (c) Demarcation line (red arrow) with abnormal microvascular and microsurface by magnified endoscopy. (d) Chromoendoscopy with indigo carmine dye. (e) Completed circumferential endoscopic marking for resection margin of lesion. (f) Endoscopic mucosal incision and submucosal dissection. (g) A submucosal vessel was identified (yellow arrow) and hemostasis by Coagrasper hemostatic forceps. (h) Resection area after dissection and hemostasis. (i) Resected specimen of gastric lesion.
The patient and lesion characteristics that were treated by endoscopic submucosal dissection.
| Procedure, n | ESD# = 13 |
|---|---|
| Age, mean ± SD (years) | 62.6 ± 7.1 |
| Sex, male/female | 2/11 |
| Macroscopic, | |
| 0-I | 7 (53.85) |
| 0-IIa | 4 (30.77) |
| 0-IIb | 1 (7.69) |
| 0-IIc | 0 (0) |
| 0-III | 0 (0) |
| Mix | 1 (7.69) |
| Location, | |
| Upper third | 5 (38.46) |
| Middle third | 1 (7.69) |
| Lower third | 7 (53.85) |
| Position, | |
| Anterior wall | 4 (30.77) |
| Greater curvature | 4 (30.77) |
| Posterior wall | 1 (7.69) |
| Lesser curvature | 4 (30.77) |
| Lesion size, mean ± SD (mm) | 27.5 ± 8.7 |
| Lesion with ulceration, | 0 (0) |
| Prior treatment, | |
| EMR## only | 1 (7.69) |
| Combination (EMR, APC###) | 0 (0) |
#ESD: endoscopic submucosal dissection; ##EMR: endoscopic mucosal resection; ###APC: argon plasma coagulation.
Outcomes of endoscopic submucosal dissection for gastric lesions.
| Procedure | ESD# = 13 |
|---|---|
| Operative duration, mean ± SD (minutes) | 145.5 ± 61.8 |
| En bloc resection, | 13 (100) |
| Incomplete resection, | 0 (0) |
| Size of lesion (mm) | 27.5 ± 8.7 |
| Size of resection specimen (mm) | 31.8 ± 10.4 |
| Specimen area/lesion area ratio | 1.16 ± 0.06 |
| Postoperative hospitalization, mean ± SD (days) | 5.2 ± 0.9 |
| Adverse events, | 1 (7.69) |
| Early (within 24 hours), | |
| Bleeding | 0 |
| Perforation | 0 |
| Late, | |
| Bleeding | 1 (7.69) |
| Perforation | 0 |
| Stricture | 0 |
| Pathological diagnosis, | |
| Adenoma | 2 (15.38) |
| Adenocarcinoma | 4 (30.77) |
| Intramucosal | 1 (7.69) |
| SM$ < 500 | 2 (15.38) |
| SM$ ≥ 500 | 1 (7.69) |
| Lymphovascular invasion | 0 (0) |
| Low-grade dysplasia | 3 (23.08) |
| High-grade dysplasia | 4 (30.77) |
| R0 resection | 13 (100) |
| Recurrence, | 0 (0) |
| Survival, | 13 (100) |
| Mean follow-up (days) | 502 ± 236 |
#ESD: endoscopic submucosal dissection; $SM: submucosa.
Details of 13 patients treated by endoscopic submucosal dissection.
| Patient number | Age (years) | Sex | ASA | Macroscopic | Location | Tumor size (mm) | Ulceration | Procedure time (minutes) | Pathological diagnosis | R0 | Depth | Adverse events | Hospital stay (day) | Recurrence | Survival | Remarkable |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 58 | Female | 1 | 0-IIa | Lower, greater curvature | 24 | No | 118 | Low-grade dysplasia | Yes | Intramucosal | No | 4 | No | Alive | |
| 2 | 62 | Female | 1 | 0-I | Lower, anterior wall | 27 | No | 135 | High-grade dysplasia | Yes | Intramucosal | No | 5 | No | Alive | |
| 3 | 69 | Male | 2 | 0-I | Lower, anterior wall | 25 | No | 120 | Adenocarcinoma | Yes | Intramucosal | No | 6 | No | Alive | |
| 4 | 68 | Female | 1 | 0-IIb | Lower, posterior wall | 25 | No | 130 | High-grade dysplasia | Yes | Intramucosal | No | 5 | No | Alive | |
| 5 | 57 | Female | 1 | 0-I | Upper, anterior wall | 22 | No | 168 | Low-grade dysplasia | Yes | Intramucosal | No | 5 | No | Alive | |
| 6 | 79 | Female | 1 | 0-IIa | Middle, greater curvature | 28 | No | 70 | High-grade dysplasia | Yes | Intramucosal | Bleeding on the 3rd day | 7 | No | Alive | |
| 7 | 63 | Female | 1 | 0-I with scar (previous EMR) | Lower, lesser curvature | 30 | No | 185 | Adenocarcinoma | Yes | Submucosa (<500 | No | 6 | No | Alive | |
| 8 | 53 | Female | 1 | 0-I | Upper, posterior wall | 20 | No | 170 | Adenoma | Yes | Intramucosal | No | 4 | No | Alive | |
| 9 | 65 | Female | 2 | 0-IIa | Lower, lesser curvature | 28 | No | 105 | Adenocarcinoma | Yes | Submucosa (≥500 | No | 6 | No | Alive | Surgery |
| 10 | 65 | Female | 1 | 0-IIa | Upper, greater curvature | 26 | No | 155 | High-grade dysplasia | Yes | Intramucosal | No | 4 | No | Alive | |
| 11 | 63 | Female | 1 | 0-I | Upper, greater curvature | 22 | No | 140 | Adenoma | Yes | Intramucosal | No | 4 | No | Alive | |
| 12 | 60 | Male | 1 | 0-I | Upper, lesser curvature | 55 | No | 317 | Adenoma | Yes | Intramucosal | No | 6 | No | Alive | |
| 13 | 52 | Female | 1 | 0-IIa+0-IIc | Lower, lesser curvature | 25 | No | 78 | Adenocarcinoma | Yes | Submucosa (<500 | No | 5 | No | Alive |